Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Clear Cell Renal Cell Carcinoma
Clinical trial register · China

Clear Cell Renal Cell Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Shanghai 3 Hangzhou 1 Hubei 1 Suzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Shanghai3 Hangzhou1 Hubei1 Suzhou1
All 12 locations
Target enrolment
to

Clear Cell Renal Cell Carcinoma trials in China

14 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Liangyou Gu
Early Phase 1
6
Beijing
2026-11
Not yet open
68Ga- and 18F-CAIX PET Imaging Study
NCT07875946Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor
Peking University First Hospital
Early Phase 1
100
Beijing
2026-10-01
Recruiting
CAIX-targeted PET/CT in Solid Tumors
NCT07833085Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer
Zhongnan Hospital
Not applicable
100
Wuhan
2026-09-21
Recruiting
Hangzhou Huasai Biomedicine Co., Ltd.
Phase 1
15
Beijing
2026-08-23
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
25
Guangzhou
2025-11-21
By invitation
Peking Union Medical College Hospital
Phase 2
100
Beijing
2025-07-01
Recruiting
Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
NCT07909265Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
54
Beijing
2025-04-01
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
NCT06519760Carbonic Anhydrase IX, PET-CT, Clear Cell Renal Cell Carcinoma
Peking University First Hospital
Not applicable
200
Beijing
2024-07-30
Recruiting
Fudan University
Phase 2
80
Shanghai
2024-06-01
Recruiting
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
NCT06613269Clear Cell Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2
40
Beijing
2024-03-27
Active, closed
RenJi Hospital
Phase 2
28
Shanghai
2023-08-23
Recruiting
Mingzhao Xiao
Observational
800
Chongqing
2022-09-01
Recruiting
Qianfoshan Hospital
Observational
300
Jinan
2022-02-11
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/clear-cell-renal-cell-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Clear Cell Renal Cell Carcinoma.

How many Clear Cell Renal Cell Carcinoma trials are recruiting in China?

10 of the 14 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Clear Cell Renal Cell Carcinoma), 14 studies
PhaseStudiesRecruitingShare
Phase 26442.9%
Early Phase 12014.3%
Not applicable2214.3%
Observational2214.3%
Phase 1117.1%
Phase 3117.1%

Most active sponsors

Lead sponsors with the most studies (Clear Cell Renal Cell Carcinoma)
Lead sponsorStudiesRecruiting
Peking Union Medical College Hospital21
Peking University First Hospital21
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Fudan University11
Hangzhou Huasai Biomedicine Co., Ltd.11
Liangyou Gu10
Mingzhao Xiao11
Qianfoshan Hospital11
RenJi Hospital10
Sun Yat-sen University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.